Company:Green Cross (South Korean company)

From HandWiki
Short description: Pharmaceutical company in Yongin, South Korea
GC Biopharma(Green Cross Corporation)
FoundedOctober 5, 1967
HeadquartersYongin, South Korea
Key people
Eun Chul Huh (President)
ServicesManufacturing and sales of biotheapeutics.
Websitehttp://gcbiopharma.com/
http://www.globalgreencross.com/eng/index.do

GC Biopharma [Green Cross Corporation] (

Short description: Securities exchange operator in South Korea
Korea Exchange
한국거래소
TypeStock exchange
LocationBusan & Seoul, South Korea
Coordinates [ ⚑ ] 35°08′12″N 129°03′53″E / 35.136721°N 129.064746°E / 35.136721; 129.064746 (Busan)
Founded1956; 70 years ago (1956)
Key peopleSohn Byung-doo
(Chairman & CEO)
CurrencySouth Korean won
No. of listings2,445 (as of May 2021)[1]
Market cap₩2,604 trillion KRW ($2.3 trillion USD)[2]
IndicesKOSPI
KOSDAQ
KRX 100
Websitewww.krx.co.kr
eng.krx.co.kr
Green Cross
Hangul
한국거래소
Hanja
韓國去來所
Revised RomanizationHanguk Georaeso
McCune–ReischauerHanguk Kŏraeso

Korea Exchange (KRX, 한국거래소) is the sole securities exchange operator in South Korea . It is headquartered in Busan, and has an office for cash markets and market oversight in Seoul.

History

The Korea Exchange was created through the integration of Korea Stock Exchange (KSE), Korea Futures Exchange and KOSDAQ Stock Market under the Korea Stock & Futures Exchange Act. The securities and derivatives markets of former exchanges are now business divisions of Korea Exchange: the Stock Market Division, KOSDAQ Market Division and Derivatives Market Division. As of Dec 2020, Korea Exchange had 2,409 listed companies with a combined market capitalization of ₩2.3 quadrillion KRW (US$2.1 trillion). The exchange has normal trading sessions from 09:00 am to 03:30 pm on all days of the week except Saturdays, Sundays and holidays declared by the Exchange in advance.[3]

On 22 May 2015, the Korea Exchange joined the United Nations Sustainable Stock Exchanges initiative in an event with the UN-SG Ban Ki-moon in attendance, as well as senior officials from UN Global Compact and UNCTAD.[4]

Traded Instruments

KOSPI Market Division
  • Stocks
  • Bonds
  • Exchange Traded Funds (ETFs)
  • Exchange-Linked Warrants (ELWs)
  • Real Estate Investment Trusts (REITs)
KOSDAQ Market Division
  • Stocks
Derivatives Market Division
  • Index Instruments: KOSPI 200 Index Futures, KOSTAR Futures, KOSPI 200 Index Options
  • Single Stock Futures
  • Equity Options
  • Interest Rate Instruments: 3-Year KTB (Korea Treasury Bond) Futures, 5-Year KTB Futures, 10-Year KTB Futures
  • Foreign Exchange Instruments: USD Futures, JPY Futures, EUR Futures, USD Options
  • Commodity Instruments: Gold Futures, Mini-gold Futures, Lean Hog Futures

See also

References

  1. ↑ ""Global KRX About KRX KRX Overview History"". http://global.krx.co.kr/main/main.jsp. 
  2. ↑ ""시가총액"". http://www.krx.co.kr/main/main.jsp. 
  3. ↑ Market Hours, Korea Exchange via Wikinvest
  4. ↑ "UN Secretary-General Joins Business Leaders in Seoul, Calls for Urgent Action on Poverty, Climate Change and Conflict". UN Global Compact. https://www.unglobalcompact.org/news/1881-05-19-2015. 



) is a biopharmaceutical company headquartered in Yongin, South Korea .

GC Biopharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease.

GC Biopharma was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of biotherapeutics, including plasma proteins, recombinant antibodies, and vaccines. Green Cross developed "Hepavax B", the world's third hepatitis B vaccine, in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene", the world's 4th recombinant antihemophilic drug, and the world's second treatment of Hunter syndrome “Hunterase” in 2012.

As part of GC Biopharma's global strategies, there are three operations based in the overseas as of 2016.

  • GC China was established in Anhui Province, China and, has produced plasma derivative products. GC China has established a pharmaceutical wholesaler in 2012.
  • GCAM was established in December 2009 to secure plasma supply and enter into the US market. The company, currently runs a total of 8 plasma centers in the US, and collects 400,000 liters of plasma a year that meets FDA standards for facilities and quality and supplies it to Green Cross.
  • GCBT is a Montreal-based biopharmaceutical company that was established in 2014 and is Green Cross’ business expansion into the North American and European markets. Building a state-of-the-art manufacturing facility for plasma proteins, GCBT will become the only intravenous immunoglobulin and albumin producer in Canada. It will also serve as a North American hub for the distribution of a variety of therapeutic products from the Green Cross family.[1]
  • MOGAM Institute [2] was established in 1984 by Dr. Young-sup Huh who was the first CEO and chairman of GC Biopharma (Green Cross Corporation). In 1970, he dedicated his life to create a sustainable biopharmaceutical industry in South Korea for the benefit of Koreans. Since then, his work led to the development of the world's third Hepatitis B vaccine. In 1984, Dr. Huh founded the MOGAM Institute using all of the profit generated from Green Cross Pharmaceuticals. Since its inception, MOGAM has made significant contributions to Korea's biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins.

Products

  • Plasma proteins
  • Recombinant antibody and proteins
  • Vaccines
  • Prescription drugs
  • Consumer healthcare

References

  1. ↑ Greencross.com, "History"
  2. ↑ MOGAM Institute for Biomedical Research, "MOGAM Institute"



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Green_Cross_(South_Korean_company)&oldid=232327"